Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome

Virology Journal

Åke Lundkvist¹  Isabelle Leparc-Goffart²  Philippe Buchy³  Jakob Bergström¹  Maria Wahlström¹  Anne Tuiskunen² 

[1] Swedish Institute for Communicable Disease Control, Solna, Sweden;Virology Department, French Army Forces Biomedical Institute (IRBA), Marseille, France;Virology Unit, Institut Pasteur in Cambodia, Phnom Penh, Cambodia

关键词: flavivirus;    dengue hemorrhagic fever;    cytokines;    clinical isolate;    tropism;    mouse model;    dengue virus;   

Others  :  1156318
DOI  :  10.1186/1743-422X-8-398

 received in 2011-07-28, accepted in 2011-08-11,  发布年份 2011

【 摘 要 】

Background

Dengue virus (DENV) infection is the most common arthropod-borne viral disease in man and there are approximately 100 million infections annually. Despite the global burden of DENV infections many important questions regarding DENV pathogenesis remain unaddressed due to the lack of appropriate animal models of infection and disease. A major problem is the fact that no non-human species naturally develop disease similar to human dengue fever (DF) or dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Apart from other risk factors for severe dengue such as host genetics and secondary infection with a heterologous DENV, virus virulence is a risk factor that is not well characterized.

Results

Three clinical DENV-1 isolates from Cambodian patients experiencing the various forms of dengue disease (DF, DHF, and DSS) were inoculated in BALB/c mice at three different concentrations. The DENV-1 isolates had different organ and cell tropism and replication kinetics. The DENV-1 isolate from a DSS patient infected the largest number of mice and was primarily neurotropic. In contrast, the DENV-1 isolates from milder clinical dengue cases infected predominantly lungs and liver, and to a lesser extent brain. In addition, infection with the DENV isolate derived from a DSS patient persisted for more than two weeks in a majority of mice compared to the other DENV-1 isolates that peaked during the first week.

Conclusions

These results confirm the in vitro findings of the same DENV-1 isolates, that showed that the isolate derived from a DSS patient can be distinguished based on phenotypic characteristics that differ from the isolates derived from a DF and DHF case [1]. We observed in this study that the DSS virus isolate persist longer in vivo with extensive neuroinvasion in contrast to the other DENV-1 isolates originating in milder human cases. Genomic characterization of the three clinical isolates identified six amino acid substitutions unique for the DSS isolates that were located both in structural genes (M and E) and in non-structural genes (NS1, NS3, and NS5). The characterization of these clinically distinct DENV-1 isolates highlight that DENVs within the same genotype may have different in vivo phenotypes.

Highlights

• Clinical DENV-1 isolates have different organ tropism in BALB/c mice.

• The isolate from a DSS patient is primarily neurotropic compared to the other isolates.

• The DENV-1 isolates have different in vivo replication kinetics.

• The isolate from a DSS patient persists longer compared to the other isolates.

• These phenotypic differences confirm our earlier in vitro findings with the same DENV-1 isolates. Thus, DENVs within the same serotype and genotype may differ enough to affect clinical conditions in vivo.

【 授权许可】

   
2011 Tuiskunen et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Tuiskunen A, Monteil V, Plumet S, Boubis L, Wahlstrom M, Duong V, Buchy P, Lundkvist A, Tolou H, Leparc-Goffart I: Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Arch Virol 2011, in press.
• [2]Rice CM, et al.: Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985, 229(4715):726-33.
• [3]Chambers TJ, et al.: Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990, 44:649-88.
• [4]Halstead SB: Pathogenesis of dengue: challenges to molecular biology. Science 1988, 239(4839):476-81.
• [5]WHO: Dengue: guidelines for diagnosis, treatment, prevention and control -- New edition. World Health Organization; 2009.
• [6]Gibbons RV, Vaughn DW: Dengue: an escalating problem. BMJ 2002, 324(7353):1563-6.
• [7]Sakuntabhai A, et al.: A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005, 37(5):507-13.
• [8]An J, et al.: Development of a novel mouse model for dengue virus infection. Virology 1999, 263(1):70-7.
• [9]Blaney JE Jr, et al.: Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 2002, 300(1):125-39.
• [10]Lin YL, et al.: Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 1998, 72(12):9729-37.
• [11]Atrasheuskaya A, et al.: Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 2003, 35(1):33-42.
• [12]Johnson AJ, Roehrig JT: New mouse model for dengue virus vaccine testing. J Virol 1999, 73(1):783-6.
• [13]Lee E, et al.: Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 2006, 87(Pt 10):2791-801.
• [14]Chen ST, et al.: CLEC5A is critical for dengue-virus-induced lethal disease. Nature 2008, 453(7195):672-6.
• [15]Prestwood TR, et al.: A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol 2008, 82(17):8411-21.
• [16]Shresta S, et al.: Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 2006, 80(20):10208-17.
• [17]Barreto DF, et al.: Histopathological and ultrastructural aspects of mice lungs experimentally infected with dengue virus serotype 2. Mem Inst Oswaldo Cruz 2007, 102(2):175-82.
• [18]Paes MV, et al.: Liver injury and viremia in mice infected with dengue-2 virus. Virology 2005, 338(2):236-46.
• [19]Huang KJ, et al.: Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol 2000, 81(Pt 9):2177-82.
• [20]Chen HC, et al.: Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol 2007, 81(11):5518-26.
• [21]Zulueta A, et al.: Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 2006, 121(1):65-73.
• [22]Navarro-Sanchez E, Despres P, Cedillo-Barron L: Innate immune responses to dengue virus. Arch Med Res 2005, 36(5):425-35.
• [23]Modis Y, et al.: Structure of the dengue virus envelope protein after membrane fusion. Nature 2004, 427(6972):313-9.
• [24]Schlesinger JJ, Brandriss MW, Walsh EE: Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 1987, 68(Pt 3):853-7.
• [25]Avirutnan P, et al.: Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193(8):1078-88.
• [26]Chambers TJ, Grakoui A, Rice CM: Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol 1991, 65(11):6042-50.
• [27]Gorbalenya AE, et al.: N-terminal domains of putative helicases of flavi- and pestiviruses may be serine proteases. Nucleic Acids Res 1989, 17(10):3889-97.
• [28]Bazan JF, Fletterick RJ: Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 1989, 171(2):637-9.
• [29]Bente DA, Rico-Hesse R: Models of dengue virus infection. Drug Discov Today Dis Models 2006, 3(1):97-103.
• [30]Gil L, et al.: The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 2009, 22(1):23-30.
• [31]Mota J, Rico-Hesse R: Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 2009, 83(17):8638-45.
• [32]Ferreira GP, et al.: Dengue virus 3 clinical isolates show different patterns of virulence in experimental mice infection. Microbes Infect 2010, 12(7):546-54.
• [33]Chaturvedi UC, et al.: Breakdown of the blood-brain barrier during dengue virus infection of mice. J Gen Virol 1991, 72(Pt 4):859-66.
• [34]Lin CF, et al.: Autoimmune pathogenesis in dengue virus infection. Viral Immunol 2006, 19(2):127-32.
• [35]Crabtree MB, Kinney RM, Miller BR: Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses. Arch Virol 2005, 150(4):771-86.
• [36]Chaturvedi UC, et al.: Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 2000, 28(3):183-8.
• [37]Chaturvedi UC, Raghupathy R, Pacsa AS, Elbishbishi EA, Agarwal R, Nagar R, Misra A, Kapoor S, mathur A, Khan MAY, Azizieh F: Shift from a Th1-type response to Th2-type in dengue hemorrhagic fever. Curr Sci 1999, 76:63-69.
• [38]Green S, et al.: Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol 1999, 59(3):329-34.
• [39]Azeredo EL, et al.: Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology 2001, 204(4):494-507.
• [40]Chakravarti A, Kumaria R: Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. Indian J Med Res 2006, 123(1):25-30.
• [41]Yang KD, et al.: A model to study cytokine profiles in primary and heterologously secondary Dengue-2 virus infections. Acta Virol 1995, 39(1):19-21.
• [42]Yang KD, Wang CL, Shaio MF: Production of cytokines and platelet activating factor in secondary dengue virus infections. J Infect Dis 1995, 172(2):604-5.
• [43]WHO: Dengue haemorrhagic fever. Diagnosis, treatment, prevention and control. 2nd edition. Geneva: WHO; 1997:12-23.
• [44]Reynes JM, et al.: Improved molecular detection of dengue virus serotype 1 variants. J Clin Microbiol 2003, 41(8):3864-7.
• [45]Leparc-Goffart I, et al.: Development and validation of real-time one-step reverse transcription-PCR for the detection and typing of dengue viruses. J Clin Virol 2009, 45(1):61-6.
• [46]Vene S, Mangiafico J, Niklasson B: Indirect immunofluorescence for serological diagnosis of dengue virus infections in Swedish patients. Clin Diagn Virol 1995, 4(1):43-50.